Glenmark Pharma Launches 8.4% Sodium Bicarbonate Injection in US Market

Glenmark Pharmaceuticals Inc., USA, has officially launched the 8.4% Sodium Bicarbonate Injection USP, 50mEq/50mL single-dose vial, marking its entry into a significant segment of the injectable pharmaceutical market. The product is bioequivalent and therapeutically equivalent to Abbott Laboratories’ sodium bicarbonate injection, positioning Glenmark to tap into a market estimated to generate $63.8 million annually.

This launch is a strategic move aimed at strengthening Glenmark’s presence within the injectable pharmaceutical space in North America. The company expands its portfolio with a quality, affordable alternative, reinforcing its commitment to accessible healthcare solutions.

Marc Kikuchi, President and Business Head, North America, highlighted this launch as a key step in Glenmark’s portfolio expansion. The company also has a Board meeting scheduled for November 14, 2025, to discuss financial results.

Key Highlights:

Launch of 8.4% Sodium Bicarbonate Injection USP, 50mEq/50mL single-dose vial

Product bioequivalent to Abbott Laboratories’ reference drug

Targets $63.8 million market segment in injectable pharmaceuticals

Strategic portfolio expansion in North America by Glenmark Pharmaceuticals Inc.

Board meeting scheduled for November 14, 2025, for financial results approval

Trading Window Closure in effect from Sept 30 to Nov 16, 2025

Sources: ScanX Trade, Marc Kikuchi statement, Glenmark Pharmaceuticals Ltd official release